CardioGenics(OTC) CGNH

CardioGenics Holdings Inc. specializes in the development and global distribution of diagnostic testing solutions in the in vitro diagnostics (IVD) sector. The company offers innovative products aimed at improving patient care through advanced diagnostic capabilities.

Products and Services

• QL Care Analyzer, a portable point-of-care immunoassay device
• Immunoassay panels for detecting cardiac biomarkers
• Paramagnetic beads for immunoassay procedures in clinical and research settings

Growth Outlook

• Expansion into international markets, including Europe and Canada
• Increasing demand for point-of-care testing solutions
• Focus on innovative product development to enhance diagnostic accuracy

Financial Highlights

• Recent quarterly net income of -$125,292, indicating ongoing operational challenges
• Trailing twelve months (TTM) revenue of $0, reflecting the need for strategic growth initiatives
• Current ratio of 0.029, highlighting liquidity concerns

CardioGenics Holdings Inc. operates within the healthcare sector, specifically focusing on medical diagnostics and research. The company has developed the QL Care Analyzer, which is designed to provide rapid and accurate diagnostic results at the point of care. This innovation is particularly significant in emergency medical situations where timely diagnosis can be critical. Despite facing financial challenges, including a recent quarterly net income loss and a TTM revenue of $0, the company is positioned to capitalize on the growing demand for point-of-care testing solutions. The focus on expanding into international markets and enhancing product offerings may provide avenues for future growth. Investors may find interest in the company's potential to innovate and adapt within a rapidly evolving healthcare landscape.